初治肺结核患者预防性保肝治疗的临床分析

发布时间：2018-03-18 18:50

本文选题：抗结核药　切入点：肺结核　出处：《中华肿瘤防治杂志》2016年S1期 　论文类型：期刊论文

【摘要】：目的通过对初治肺结核引起的药物性肝炎中治疗方案的变整,研究对其治疗效果的影响。方法选取2004-06-2015-07保定市传染病医院114例经初次肺结核治疗的患者。随机分为对照组和实验组,每组各57例,对照组不进行干预治疗,实验组采取干预治疗即调整用药方案,最终对预后结果进行统计分析。结果对照组中肝功正常者占68.4%,低于实验组的94.7%;肝功异常者中,对照组轻度(17.5%)、中度(12.3%)和重度(1.8%)均高于实验组的轻度(3.5%)、中度(1.8%)和重度(0);其中,实验组出现停药者1例(1.8%)要选低于对照组的11例(19.3%),差异均有统计学意义,P0.05;对照组和实验组的转阴率分别为63.2%和64.9%,差异无统计学意义,P0.05。结论在通过对肺结核初次治疗产生肝炎的患者进行针对性的干预治疗,可以有效的减少药物性肝炎的发生率以及损害程度,而且对于最终治疗的效果不会产生影响。
[Abstract]:Objective to change the treatment scheme of drug-induced hepatitis caused by primary pulmonary tuberculosis. Methods 114 patients treated with primary pulmonary tuberculosis in Baoding Infectious Disease Hospital were randomly divided into control group (n = 57) and experimental group (n = 57). Results the patients with normal liver function in the control group accounted for 68.4%, which was lower than that in the experimental group (94.7%), and in the patients with abnormal liver function, the patients with abnormal liver function accounted for 68.4%. The control group was higher than the experimental group (3.5g / L, 1.8cm) and 1.8cm (n = 12.3C) and the control group (n = 17.5) and the control group (n = 17.5g) and the control group (n = 12.3g) and the control group (n = 1). There was no significant difference in the negative conversion rate between the control group (63.2% cases) and the experimental group (64.9%). Conclusion in the first treatment of pulmonary tuberculosis, there is no significant difference between the two groups (P 0.05). Patients with hepatitis were treated with targeted intervention, It can effectively reduce the incidence and severity of drug-induced hepatitis, and will not affect the outcome of the final treatment.
【作者单位】：保定市传染病医院结核一科;
【分类号】：R521

【参考文献】